Table 4.
Representative nanomedicine targets and design of HMs
| Targets | Carrier | Drug | Ind. | Outcome | References |
|---|---|---|---|---|---|
| CD19 | Liposome | DOX | ALL | Significantly prolonged the survival of mice | [205] |
| LNP | C61 | ALL | Consistently caused apoptosis in B-precursor ALL cells | [58] | |
| Au NPs | NB | ALL | Proved superior cytotoxic effect against CCRF-SB cells | [206] | |
| CD3 | Gelatin NPs | ALL | Significantly increased cell absorption and internalization | [207] | |
| B220 | MSN | DNR | AML | Efficiently incorporated into and preferentially kill LSCs | [209] |
| CD117 | CPSNPs | ICG | CML | In vivo efficacy of PDT was dramatically enhanced | [210] |
| CD123 | PMBN | PTX/GA-A | AML | Increased anti proliferation of cells | [211] |
| CdTe QDs | DNR | MDS | Effectively inhibited the tumor growth of MDS-bearing nude mice | [216] | |
| IL-1RAP | Cas9 RNP | MSCM-NF | AML | Reduced LSC colony-forming capacity and leukemic burden | [212] |
| CD71 | Fn | Arsenic | AML | Exerted strong antileukemia effects in diverse xenograft models | [202] |
| PTK7 | MS2 | Porphyrins | AML | Killed Jurkat cells selectively even when mixed with erythrocytes | [204] |
| CXCR4 | Micelle | Peptide E5 | AML | Significantly inhibited the engraftment of leukemic cells in spleen and BM | [213] |
| CD44 | PLGA | PTL | AML | Improved the bioavailability and selective targeting of leukemic cells | [64] |
| FA | CS | 6-MP | ALL | Significantly elevated tumor intracellular drug release | [203] |
| CD40 | PLGA | MTV | ALL | Significantly reduced tumor volume with increased caspase-3 activity | [231] |
| CD20 | PLGA | AZD-2014 | Lyn | Significantly improved efficacy of AZD-2014 against NHL cells | [220] |
| CD22 | NK-92MI | Sialyl Lewis X | Lyn | Exhibited significantly enhanced tumor cell binding and killing | [232] |
| CD38 | PBCL | S3I-1757 | MM | Significantly reduced the tumor size by fourfold compared to S3I-NP | [227] |
| PDGFR-β | PLA | PTX | MM | Simultaneous clearance of CAF cells and MM tumor cells | [199] |
PTX Paclitaxel, C61 Spleen tyrosine kinase (SYK) P-site inhibitor, NB Nile Blue, DNR Daunorubicin, Cas9 RNP Cas9/single guide RNA (sgRNA) ribonucleoprotein [lipidoid nanoparticle (LNP)], MSCM-NF Mesenchymal stem cell membrane-coated nanofibril, PTL Parthenolide, 6-MP 6-mercaptopurine, CS Chitosan, PEO-b-PBC Poly(ethyleneoxide)-block-poly(α-benzylcarboxylate-ε-caprolactone)